Core Viewpoint - The report outlines the expected daily related transactions of Jiangsu Kangwei Century Biotechnology Co., Ltd. for the year 2025, emphasizing the necessity and fairness of these transactions in supporting the company's operational needs and market competitiveness [1][5][6]. Summary by Sections Daily Related Transactions Overview - The expected amount for daily related transactions in 2025 is estimated at 284 million yuan, with specific categories including raw material purchases and service provisions [1][5]. - The company anticipates a significant increase in transactions with Shanghai Tianhao Biotechnology Co., Ltd. due to new business developments [1][5]. Expected and Executed Transactions for 2024 - The company did not estimate or disclose related transactions for 2024 due to the small amount not meeting the board's review standards [2]. Related Parties and Relationships - Key related parties include Shanghai Tianhao Biotechnology Co., Ltd. and Beijing Kangwei, with established relationships based on shareholding and operational ties [2][3]. Main Content and Pricing Policy of Related Transactions - The main expected transactions for 2025 include vehicle leasing, office space leasing, property management services, technical services, and product sales [5]. - Pricing for these transactions will be based on market principles, ensuring fairness and non-detriment to the company's interests [5][6]. Necessity and Impact of Related Transactions - The anticipated related transactions are deemed necessary for the company's operational activities, contributing to stable business development and enhanced market competitiveness [5][6]. - The pricing of related transactions will follow fair and voluntary principles, ensuring no adverse effects on the company or its shareholders [6]. Review Procedures and Opinions - The board of directors and independent directors have reviewed and approved the related transactions, confirming compliance with legal and regulatory requirements [6][7].

Core Viewpoint - The company has reported a revenue of RMB 645.02 million for the year, representing a year-on-year growth of 18.65%, with a net profit attributable to shareholders of RMB 123.83 million, indicating strong performance in the biopharmaceutical sector [5][26]. Company Overview - The company specializes in providing recombinant proteins, antibodies, and other key biological reagents and technical services, aiming to support global biopharmaceutical companies and research institutions in drug development and production [4][5]. - The company serves major clients including top global pharmaceutical firms such as Johnson & Johnson, Pfizer, and Novartis, as well as notable domestic companies like Innovent Biologics and WuXi AppTec [5][24]. Financial Performance - The company achieved a revenue of RMB 645.02 million, with a net profit of RMB 123.83 million, reflecting a solid growth trajectory in its core business [5][26]. - The profit distribution plan approved by the board includes a cash dividend of RMB 4.00 per 10 shares and a capital reserve transfer of 5 shares for every 10 shares held [3]. Product and Service Offerings - The main products include recombinant proteins, antibodies, and various assay kits, which are essential for drug development and clinical research [5][8]. - The company has developed nearly 50 high-quality GMP-grade products, ensuring compliance with stringent quality management standards [6][18]. Market Applications - The company's products are widely used in antibody drug development, cell and gene therapy, antibody-drug conjugates (ADCs), and neuroscience research, addressing critical needs in these rapidly evolving fields [17][19][20]. - The company provides comprehensive solutions for CAR-T cell therapy development, including specific antibodies and reagents for quality assessment [17]. Business Model - The company employs a procurement model that emphasizes supplier management and quality control, ensuring a steady supply of essential raw materials for production [21]. - The production process follows a structured approach, with rigorous quality control measures in place to maintain high standards [22][23]. - The sales strategy leverages both online and offline marketing channels, establishing partnerships with leading companies in the biotechnology and life sciences sectors to enhance market reach [24].